Document is current
Any future updates will be listed below
-
Authors
Dahlin, Jayme L. https://orcid.org/0000-0003-4151-9944
Hua, Bruce K. https://orcid.org/0000-0002-7330-2312
Zucconi, Beth E.
Nelson, Shawn D. Jr
Singh, Shantanu https://orcid.org/0000-0003-3150-3025
Carpenter, Anne E. https://orcid.org/0000-0003-1555-8261
Shrimp, Jonathan H. https://orcid.org/0000-0001-9872-942X
Lima-Fernandes, Evelyne
Wawer, Mathias J. https://orcid.org/0000-0001-6664-0930
Chung, Lawrence P. W.
Agrawal, Ayushi https://orcid.org/0000-0003-2940-8926
O’Reilly, Mary
Barsyte-Lovejoy, Dalia https://orcid.org/0000-0002-6560-9621
Szewczyk, Magdalena
Li, Fengling
Lak, Parnian
Cuellar, Matthew https://orcid.org/0000-0003-3365-2120
Cole, Philip A. https://orcid.org/0000-0001-6873-7824
Meier, Jordan L. https://orcid.org/0000-0002-0537-7101
Thomas, Tim https://orcid.org/0000-0002-7623-8344
Baell, Jonathan B. https://orcid.org/0000-0003-2114-8242
Brown, Peter J. https://orcid.org/0000-0002-8454-0367
Walters, Michael A. https://orcid.org/0000-0001-5650-9277
Clemons, Paul A. https://orcid.org/0000-0002-1800-5112
Schreiber, Stuart L.
Wagner, Bridget K. https://orcid.org/0000-0002-2629-361X
- License Information
-
More Information
Article History
Received: 1 August 2022
Accepted: 20 February 2023
First Online: 13 March 2023
Competing interests
: P.A. Cole is a cofounder of Acylin Therapeutics and has been a consultant to AbbVie, which have had research programs in KAT inhibitors. A.E.C. has ownership interest in, and serves on the Scientific Advisory Board of, Recursion, which uses image-based data for drug discovery. P.A. Clemons is an advisor for Pfizer, Inc., and Belharra Therapeutics. The other authors hereby declare no competing interests pertaining to the material in this manuscript.
